Faint hope for Alder as Teva bucks dismal migraine trend
Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.
12 years on, Astra draws a line under Medimmune
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Topping 2018 drug approvals will be a tall order
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
US price truce cracks but biopharma may want to tread carefully
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
Go or no go? Big decisions for Acelrx, Trevena, Loxo and Astellas
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.